RAPT Therapeutics, Inc. - RAPT STOCK NEWS

RAPT Therapeutics presented promising data at the ESMO Immuno-Oncology Congress for its ongoing Phase 1/2 trial of FLX475, showing a confirmed overall response rate of 31% in checkpoint-naïve NSCLC patients, with ongoing responses exceeding one year. Among 13 patients, 38% of those with PD-L1 positive tumors responded, while 25% responded in the PD-L1 negative group. Additionally, a separate cohort of patients with EBV+ NK/T cell lymphoma displayed four responses, including two durable complete metabolic responses. The safety profile of FLX475 remained favorable.

RAPT Therapeutics (Nasdaq: RAPT) has announced that its abstract for the ongoing Phase 1/2 study of FLX475 will be presented at the European Society for Medical Oncology Immuno-Oncology Annual Congress from December 7-9, 2022, in Geneva, Switzerland. The presentation will cover data from patients with checkpoint inhibitor-naïve NSCLC treated with FLX475 plus pembrolizumab and those with EBV-positive NK/T cell lymphoma receiving FLX475 monotherapy. The session will occur on December 8, 2022, from 12:30 to 1:15 p.m. CET.

RAPT Therapeutics announced the pricing of an underwritten public offering of 4,054,055 shares of common stock at $18.50 per share, aiming to raise approximately $75 million before expenses. The offering will close on November 22, 2022. The underwriters have an additional option to purchase up to 608,108 shares. This offering falls under a shelf registration statement declared effective on November 16, 2020. The company focuses on developing oral small molecule therapies for inflammatory diseases and oncology, with drug candidates targeting CCR4.

RAPT Therapeutics has announced an underwritten public offering of $75 million in common stock, with an option for underwriters to purchase an additional $11.25 million. The offering, subject to market conditions, is being managed by J.P. Morgan, Evercore ISI, Guggenheim Securities, and Cantor. The shares will be offered under a previously declared effective registration statement by the SEC. This capital raise aims to support RAPT's continued development of oral small molecule therapies for inflammatory diseases and oncology.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) reported a net loss of $21.2 million for Q3 2022, compared to $18.7 million in Q3 2021. Over the nine months ending September 30, 2022, the net loss totaled $60.9 million, an increase from $51.3 million year-over-year. Research and development expenses rose to $16.6 million for Q3 and $47.6 million for the nine months, driven by early-stage program costs. The company's cash position remains strong at $195.4 million, supporting ongoing clinical trials for RPT193 and FLX475.

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 – RAPT Therapeutics (Nasdaq: RAPT) announced participation in three upcoming investor conferences in November. The conferences include the Guggenheim 4th Annual Immunology and Neurology Day on November 15, the Piper Sandler 33rd Annual Healthcare Conference on November 29, and the Evercore ISI 5th Annual Virtual HealthCONx Conference on November 30. Interested parties can access live webcasts and recordings through the RAPT Therapeutics website.

RAPT Therapeutics has announced the appointment of Jennifer Nicholson as Senior Vice President of Regulatory Affairs and Quality Assurance, and Adnan Rahman as Vice President of Commercial. These appointments come at a crucial time as the company progresses its RPT193 program into late-phase trials for atopic dermatitis and asthma, and continues developing FLX475 for various cancers. Both executives bring extensive experience from notable biopharmaceutical companies, which will enhance RAPT's regulatory and commercial strategies.

RAPT Therapeutics announced participation in key investor conferences throughout September 2022. The events include Citi’s 17th Annual Biopharma Conference on September 7, Wells Fargo Healthcare Conference on September 8 featuring a fireside chat with President and CEO Brian Wong, and H.C. Wainwright 24th Annual Global Investment Conference on September 12, available on-demand. RAPT is focused on developing small molecule therapies for inflammatory diseases and oncology, including drug candidates RPT193 and FLX475. For live webcasts, visit their website.

RAPT Therapeutics, a clinical-stage biopharmaceutical company, reported financial results for Q2 and the first half of 2022, marking a net loss of $19.2 million for Q2, compared to $16.1 million in Q2 2021. R&D expenses rose to $14.4 million from $13.2 million, driven by costs associated with RPT193. General and administrative expenses also increased to $5.4 million, up from $3.8 million. The company maintains a robust cash position of $207.3 million, bolstered by a $50 million financing. Future plans include expanding RPT193 trials and advancing FLX475.